查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1876008

結合疫苗：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Conjugate Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 107 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024年全球結合疫苗市場規模估計為106.4億美元，預計到2031年將成長至132.24億美元，在2025年至2031年的預測期內，複合年成長率為3.2%。

本報告從跨境產業佈局、資本配置模式、區域經濟相互依存以及供應鏈重組等方面，對近期有關結合疫苗的關稅調整和國際戰略反制措施進行了全面評估。

疫苗透過誘導身體對抗原產生免疫反應來預防疾病。抗原是細菌或病毒的外來成分，能被免疫系統辨識。結合疫苗的設計理念是將弱抗原與強抗原結合，後者作為載體，使免疫系統對弱抗原產生更強的免疫反應。

結合疫苗市場正經歷顯著成長，主要驅動力來自全球對感染疾病預防日益成長的關注，尤其是在嬰兒童和老年人群體中。結合疫苗透過將弱抗原與強載體蛋白連接來增強免疫反應，已被證明對B型流感嗜血桿菌（Hib）、肺炎球菌和腦膜炎球菌病菌感染具有高效性。各國政府的免疫規劃和公共衛生舉措，尤其是在新興經濟體，正在推動疫苗接種覆蓋率的提高，從而刺激市場需求。此外，全球疫苗免疫聯盟（GAVI）、世界衛生組織（WHO）和聯合國兒童基金會（UNICEF）等國際衛生組織的加大投入，以及人們對早期接種疫苗重要性的認知不斷提高，也進一步推動了疫苗的普及。疫苗研發領域的技術進步，例如改進的結合方法和新型載體蛋白的開發，使得生產更有效、保護更廣泛的疫苗成為可能，從而促進了疫苗創新和市場擴張。

然而，結合疫苗市場面臨許多挑戰。高昂的研發和生產成本，尤其是多效價疫苗，可能會限制低收入地區的可近性和可負擔性。嚴格的監管要求和漫長的臨床試驗週期會延緩產品核可，並對新參與企業和中小型生物技術公司構成障礙。偏遠和低度開發地區的低溫運輸物流和儲存要求也帶來了額外的挑戰，並可能影響疫苗的分發和效力。由於錯誤訊息和公眾對免疫規劃缺乏信任而導致的疫苗猶豫，也對市場成長構成日益成長的風險。此外，來自mRNA疫苗和蛋白質次單元疫苗等替代疫苗技術的競爭，從長遠來看可能會降低人們對結合疫苗平台的興趣。應對這些挑戰需要國際合作，以改善供應鏈，增加對研究和公共衛生基礎設施的投入，並加強對疫苗安全性和有效性的社區教育。

本報告旨在按地區/國家、類型和最終用戶對全球結合疫苗市場進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

本報告以銷售量（百萬支）和收入（百萬美元）為單位，對結合疫苗市場規模、估計值和預測進行了呈現，基準年為2024年，並涵蓋了2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定結合疫苗業務/成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Pfizer
  • GSK
  • Sanofi
  • Merck
  • Walvax Biotechnology
  • Royal（Wuxi）Bio-Pharmaceutical
  • Bharat Biotech
  • Zhifei Biologic
  • Beijing Minhai Biotechnology
  • SinoPharma

按類型分類的細分市場

  • Hib疫苗
  • 腦膜炎雙球菌疫苗
  • 肺炎鏈球菌疫苗
  • 其他

最終使用者群體

  • 兒童
  • 成人

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Conjugate Vaccine was estimated to be worth US$ 10640 million in 2024 and is forecast to a readjusted size of US$ 13224 million by 2031 with a CAGR of 3.2% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Conjugate Vaccine cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

The conjugate vaccine market is experiencing significant growth, primarily driven by the increasing global focus on preventing infectious diseases, especially among infants, children, and the elderly. Conjugate vaccines, which link a weak antigen to a strong carrier protein to enhance immune response, have proven highly effective against diseases like Haemophilus influenzae type b (Hib), pneumococcal, and meningococcal infections. Government immunization programs and public health initiatives-particularly in emerging economies-are expanding vaccine coverage, thereby fueling market demand. Additionally, rising investments from global health organizations (such as GAVI, WHO, and UNICEF), along with growing awareness of the importance of early immunization, are further boosting uptake. Technological advancements in vaccine development, including improved conjugation methods and novel carrier proteins, are enabling the production of more effective and broad-spectrum vaccines, supporting innovation and market expansion.

However, the conjugate vaccine market also faces notable challenges. High development and production costs, particularly for multivalent vaccines, can limit affordability and access in low-income regions. Stringent regulatory requirements and lengthy clinical trial timelines can delay product approvals, creating barriers for new entrants and smaller biotech firms. Cold chain logistics and storage requirements pose additional challenges in remote or underdeveloped areas, potentially impacting vaccine distribution and efficacy. Vaccine hesitancy, fueled by misinformation and lack of public trust in immunization programs, also poses a growing risk to market growth. Moreover, competition from alternative vaccine technologies, such as mRNA or protein subunit vaccines, may shift focus away from conjugate platforms in the long term. Addressing these challenges will require international collaboration to improve supply chains, expand funding for research and public health infrastructure, and enhance community education on vaccine safety and effectiveness.

This report aims to provide a comprehensive presentation of the global market for Conjugate Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Conjugate Vaccine by region & country, by Type, and by End Users.

The Conjugate Vaccine market size, estimations, and forecasts are provided in terms of sales volume (Million Unit) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Conjugate Vaccine.

Market Segmentation

By Company

  • Pfizer
  • GSK
  • Sanofi
  • Merck
  • Walvax Biotechnology
  • Royal (Wuxi) Bio-Pharmaceutical
  • Bharat Biotech
  • Zhifei Biologic
  • Beijing Minhai Biotechnology
  • SinoPharma

Segment by Type

  • Hib Vaccine
  • Meningococcal Vaccine
  • Pneumococcal Vaccine
  • Others

Segment by End Users

  • Children
  • Adult

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Conjugate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by End Users, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Conjugate Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Conjugate Vaccine in country level. It provides sigmate data by Type, and by End Users for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Conjugate Vaccine Product Introduction
  • 1.2 Global Conjugate Vaccine Market Size Forecast
    • 1.2.1 Global Conjugate Vaccine Sales Value (2020-2031)
    • 1.2.2 Global Conjugate Vaccine Sales Volume (2020-2031)
    • 1.2.3 Global Conjugate Vaccine Sales Price (2020-2031)
  • 1.3 Conjugate Vaccine Market Trends & Drivers
    • 1.3.1 Conjugate Vaccine Industry Trends
    • 1.3.2 Conjugate Vaccine Market Drivers & Opportunity
    • 1.3.3 Conjugate Vaccine Market Challenges
    • 1.3.4 Conjugate Vaccine Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Conjugate Vaccine Players Revenue Ranking (2024)
  • 2.2 Global Conjugate Vaccine Revenue by Company (2020-2025)
  • 2.3 Global Conjugate Vaccine Players Sales Volume Ranking (2024)
  • 2.4 Global Conjugate Vaccine Sales Volume by Company Players (2020-2025)
  • 2.5 Global Conjugate Vaccine Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Conjugate Vaccine Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Conjugate Vaccine Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Conjugate Vaccine
  • 2.9 Conjugate Vaccine Market Competitive Analysis
    • 2.9.1 Conjugate Vaccine Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Conjugate Vaccine Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Conjugate Vaccine as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Hib Vaccine
    • 3.1.2 Meningococcal Vaccine
    • 3.1.3 Pneumococcal Vaccine
    • 3.1.4 Others
  • 3.2 Global Conjugate Vaccine Sales Value by Type
    • 3.2.1 Global Conjugate Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Conjugate Vaccine Sales Value, by Type (2020-2031)
    • 3.2.3 Global Conjugate Vaccine Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Conjugate Vaccine Sales Volume by Type
    • 3.3.1 Global Conjugate Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Conjugate Vaccine Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Conjugate Vaccine Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Conjugate Vaccine Average Price by Type (2020-2031)

4 Segmentation by End Users

  • 4.1 Introduction by End Users
    • 4.1.1 Children
    • 4.1.2 Adult
  • 4.2 Global Conjugate Vaccine Sales Value by End Users
    • 4.2.1 Global Conjugate Vaccine Sales Value by End Users (2020 VS 2024 VS 2031)
    • 4.2.2 Global Conjugate Vaccine Sales Value, by End Users (2020-2031)
    • 4.2.3 Global Conjugate Vaccine Sales Value, by End Users (%) (2020-2031)
  • 4.3 Global Conjugate Vaccine Sales Volume by End Users
    • 4.3.1 Global Conjugate Vaccine Sales Volume by End Users (2020 VS 2024 VS 2031)
    • 4.3.2 Global Conjugate Vaccine Sales Volume, by End Users (2020-2031)
    • 4.3.3 Global Conjugate Vaccine Sales Volume, by End Users (%) (2020-2031)
  • 4.4 Global Conjugate Vaccine Average Price by End Users (2020-2031)

5 Segmentation by Region

  • 5.1 Global Conjugate Vaccine Sales Value by Region
    • 5.1.1 Global Conjugate Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Conjugate Vaccine Sales Value by Region (2020-2025)
    • 5.1.3 Global Conjugate Vaccine Sales Value by Region (2026-2031)
    • 5.1.4 Global Conjugate Vaccine Sales Value by Region (%), (2020-2031)
  • 5.2 Global Conjugate Vaccine Sales Volume by Region
    • 5.2.1 Global Conjugate Vaccine Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Conjugate Vaccine Sales Volume by Region (2020-2025)
    • 5.2.3 Global Conjugate Vaccine Sales Volume by Region (2026-2031)
    • 5.2.4 Global Conjugate Vaccine Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Conjugate Vaccine Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Conjugate Vaccine Sales Value, 2020-2031
    • 5.4.2 North America Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Conjugate Vaccine Sales Value, 2020-2031
    • 5.5.2 Europe Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Conjugate Vaccine Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Conjugate Vaccine Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Conjugate Vaccine Sales Value, 2020-2031
    • 5.7.2 South America Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Conjugate Vaccine Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Conjugate Vaccine Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Conjugate Vaccine Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Conjugate Vaccine Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Conjugate Vaccine Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Conjugate Vaccine Sales Value, 2020-2031
    • 6.3.2 United States Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Conjugate Vaccine Sales Value, 2020-2031
    • 6.4.2 Europe Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Conjugate Vaccine Sales Value, 2020-2031
    • 6.5.2 China Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Conjugate Vaccine Sales Value, 2020-2031
    • 6.6.2 Japan Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Conjugate Vaccine Sales Value, 2020-2031
    • 6.7.2 South Korea Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Conjugate Vaccine Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Conjugate Vaccine Sales Value, 2020-2031
    • 6.9.2 India Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Conjugate Vaccine Sales Value by End Users, 2024 VS 2031

7 Company Profiles

  • 7.1 Pfizer
    • 7.1.1 Pfizer Company Information
    • 7.1.2 Pfizer Introduction and Business Overview
    • 7.1.3 Pfizer Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Pfizer Conjugate Vaccine Product Offerings
    • 7.1.5 Pfizer Recent Development
  • 7.2 GSK
    • 7.2.1 GSK Company Information
    • 7.2.2 GSK Introduction and Business Overview
    • 7.2.3 GSK Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 GSK Conjugate Vaccine Product Offerings
    • 7.2.5 GSK Recent Development
  • 7.3 Sanofi
    • 7.3.1 Sanofi Company Information
    • 7.3.2 Sanofi Introduction and Business Overview
    • 7.3.3 Sanofi Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Sanofi Conjugate Vaccine Product Offerings
    • 7.3.5 Sanofi Recent Development
  • 7.4 Merck
    • 7.4.1 Merck Company Information
    • 7.4.2 Merck Introduction and Business Overview
    • 7.4.3 Merck Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Merck Conjugate Vaccine Product Offerings
    • 7.4.5 Merck Recent Development
  • 7.5 Walvax Biotechnology
    • 7.5.1 Walvax Biotechnology Company Information
    • 7.5.2 Walvax Biotechnology Introduction and Business Overview
    • 7.5.3 Walvax Biotechnology Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Walvax Biotechnology Conjugate Vaccine Product Offerings
    • 7.5.5 Walvax Biotechnology Recent Development
  • 7.6 Royal (Wuxi) Bio-Pharmaceutical
    • 7.6.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
    • 7.6.2 Royal (Wuxi) Bio-Pharmaceutical Introduction and Business Overview
    • 7.6.3 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Offerings
    • 7.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Development
  • 7.7 Bharat Biotech
    • 7.7.1 Bharat Biotech Company Information
    • 7.7.2 Bharat Biotech Introduction and Business Overview
    • 7.7.3 Bharat Biotech Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Bharat Biotech Conjugate Vaccine Product Offerings
    • 7.7.5 Bharat Biotech Recent Development
  • 7.8 Zhifei Biologic
    • 7.8.1 Zhifei Biologic Company Information
    • 7.8.2 Zhifei Biologic Introduction and Business Overview
    • 7.8.3 Zhifei Biologic Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Zhifei Biologic Conjugate Vaccine Product Offerings
    • 7.8.5 Zhifei Biologic Recent Development
  • 7.9 Beijing Minhai Biotechnology
    • 7.9.1 Beijing Minhai Biotechnology Company Information
    • 7.9.2 Beijing Minhai Biotechnology Introduction and Business Overview
    • 7.9.3 Beijing Minhai Biotechnology Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Beijing Minhai Biotechnology Conjugate Vaccine Product Offerings
    • 7.9.5 Beijing Minhai Biotechnology Recent Development
  • 7.10 SinoPharma
    • 7.10.1 SinoPharma Company Information
    • 7.10.2 SinoPharma Introduction and Business Overview
    • 7.10.3 SinoPharma Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 SinoPharma Conjugate Vaccine Product Offerings
    • 7.10.5 SinoPharma Recent Development

8 Industry Chain Analysis

  • 8.1 Conjugate Vaccine Industrial Chain
  • 8.2 Conjugate Vaccine Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Conjugate Vaccine Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Conjugate Vaccine Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Conjugate Vaccine Market Trends
  • Table 2. Conjugate Vaccine Market Drivers & Opportunity
  • Table 3. Conjugate Vaccine Market Challenges
  • Table 4. Conjugate Vaccine Market Restraints
  • Table 5. Global Conjugate Vaccine Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Conjugate Vaccine Revenue Market Share by Company (2020-2025)
  • Table 7. Global Conjugate Vaccine Sales Volume by Company (2020-2025) & (Million Unit)
  • Table 8. Global Conjugate Vaccine Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Conjugate Vaccine Price by Company (2020-2025) & (USD/Unit)
  • Table 10. Key Manufacturers Conjugate Vaccine Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Conjugate Vaccine Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Conjugate Vaccine
  • Table 13. Global Conjugate Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Conjugate Vaccine as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Conjugate Vaccine Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Conjugate Vaccine Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Conjugate Vaccine Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Conjugate Vaccine Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Conjugate Vaccine Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Conjugate Vaccine Sales Volume by Type: 2020 VS 2024 VS 2031 (Million Unit)
  • Table 22. Global Conjugate Vaccine Sales Volume by Type (2020-2025) & (Million Unit)
  • Table 23. Global Conjugate Vaccine Sales Volume by Type (2026-2031) & (Million Unit)
  • Table 24. Global Conjugate Vaccine Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Conjugate Vaccine Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Conjugate Vaccine Price by Type (2020-2025) & (USD/Unit)
  • Table 27. Global Conjugate Vaccine Price by Type (2026-2031) & (USD/Unit)
  • Table 28. Global Conjugate Vaccine Sales Value by End Users: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Conjugate Vaccine Sales Value by End Users (2020-2025) & (US$ Million)
  • Table 30. Global Conjugate Vaccine Sales Value by End Users (2026-2031) & (US$ Million)
  • Table 31. Global Conjugate Vaccine Sales Market Share in Value by End Users (2020-2025)
  • Table 32. Global Conjugate Vaccine Sales Market Share in Value by End Users (2026-2031)
  • Table 33. Global Conjugate Vaccine Sales Volume by End Users: 2020 VS 2024 VS 2031 (Million Unit)
  • Table 34. Global Conjugate Vaccine Sales Volume by End Users (2020-2025) & (Million Unit)
  • Table 35. Global Conjugate Vaccine Sales Volume by End Users (2026-2031) & (Million Unit)
  • Table 36. Global Conjugate Vaccine Sales Market Share in Volume by End Users (2020-2025)
  • Table 37. Global Conjugate Vaccine Sales Market Share in Volume by End Users (2026-2031)
  • Table 38. Global Conjugate Vaccine Price by End Users (2020-2025) & (USD/Unit)
  • Table 39. Global Conjugate Vaccine Price by End Users (2026-2031) & (USD/Unit)
  • Table 40. Global Conjugate Vaccine Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Conjugate Vaccine Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Conjugate Vaccine Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Conjugate Vaccine Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Conjugate Vaccine Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Conjugate Vaccine Sales Volume by Region (Million Unit): 2020 VS 2024 VS 2031
  • Table 46. Global Conjugate Vaccine Sales Volume by Region (2020-2025) & (Million Unit)
  • Table 47. Global Conjugate Vaccine Sales Volume by Region (2026-2031) & (Million Unit)
  • Table 48. Global Conjugate Vaccine Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Conjugate Vaccine Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Conjugate Vaccine Average Price by Region (2020-2025) & (USD/Unit)
  • Table 51. Global Conjugate Vaccine Average Price by Region (2026-2031) & (USD/Unit)
  • Table 52. Key Countries/Regions Conjugate Vaccine Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Conjugate Vaccine Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Conjugate Vaccine Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Conjugate Vaccine Sales Volume, (2020-2025) & (Million Unit)
  • Table 56. Key Countries/Regions Conjugate Vaccine Sales Volume, (2026-2031) & (Million Unit)
  • Table 57. Pfizer Company Information
  • Table 58. Pfizer Introduction and Business Overview
  • Table 59. Pfizer Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 60. Pfizer Conjugate Vaccine Product Offerings
  • Table 61. Pfizer Recent Development
  • Table 62. GSK Company Information
  • Table 63. GSK Introduction and Business Overview
  • Table 64. GSK Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 65. GSK Conjugate Vaccine Product Offerings
  • Table 66. GSK Recent Development
  • Table 67. Sanofi Company Information
  • Table 68. Sanofi Introduction and Business Overview
  • Table 69. Sanofi Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 70. Sanofi Conjugate Vaccine Product Offerings
  • Table 71. Sanofi Recent Development
  • Table 72. Merck Company Information
  • Table 73. Merck Introduction and Business Overview
  • Table 74. Merck Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 75. Merck Conjugate Vaccine Product Offerings
  • Table 76. Merck Recent Development
  • Table 77. Walvax Biotechnology Company Information
  • Table 78. Walvax Biotechnology Introduction and Business Overview
  • Table 79. Walvax Biotechnology Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 80. Walvax Biotechnology Conjugate Vaccine Product Offerings
  • Table 81. Walvax Biotechnology Recent Development
  • Table 82. Royal (Wuxi) Bio-Pharmaceutical Company Information
  • Table 83. Royal (Wuxi) Bio-Pharmaceutical Introduction and Business Overview
  • Table 84. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 85. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Offerings
  • Table 86. Royal (Wuxi) Bio-Pharmaceutical Recent Development
  • Table 87. Bharat Biotech Company Information
  • Table 88. Bharat Biotech Introduction and Business Overview
  • Table 89. Bharat Biotech Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 90. Bharat Biotech Conjugate Vaccine Product Offerings
  • Table 91. Bharat Biotech Recent Development
  • Table 92. Zhifei Biologic Company Information
  • Table 93. Zhifei Biologic Introduction and Business Overview
  • Table 94. Zhifei Biologic Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 95. Zhifei Biologic Conjugate Vaccine Product Offerings
  • Table 96. Zhifei Biologic Recent Development
  • Table 97. Beijing Minhai Biotechnology Company Information
  • Table 98. Beijing Minhai Biotechnology Introduction and Business Overview
  • Table 99. Beijing Minhai Biotechnology Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 100. Beijing Minhai Biotechnology Conjugate Vaccine Product Offerings
  • Table 101. Beijing Minhai Biotechnology Recent Development
  • Table 102. SinoPharma Company Information
  • Table 103. SinoPharma Introduction and Business Overview
  • Table 104. SinoPharma Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 105. SinoPharma Conjugate Vaccine Product Offerings
  • Table 106. SinoPharma Recent Development
  • Table 107. Key Raw Materials Lists
  • Table 108. Raw Materials Key Suppliers Lists
  • Table 109. Conjugate Vaccine Downstream Customers
  • Table 110. Conjugate Vaccine Distributors List
  • Table 111. Research Programs/Design for This Report
  • Table 112. Key Data Information from Secondary Sources
  • Table 113. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Conjugate Vaccine Product Picture
  • Figure 2. Global Conjugate Vaccine Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Conjugate Vaccine Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Conjugate Vaccine Sales Volume (2020-2031) & (Million Unit)
  • Figure 5. Global Conjugate Vaccine Sales Price (2020-2031) & (USD/Unit)
  • Figure 6. Conjugate Vaccine Report Years Considered
  • Figure 7. Global Conjugate Vaccine Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Conjugate Vaccine Players Sales Volume Ranking (2024) & (Million Unit)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Conjugate Vaccine Revenue in 2024
  • Figure 10. Conjugate Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Hib Vaccine Picture
  • Figure 12. Meningococcal Vaccine Picture
  • Figure 13. Pneumococcal Vaccine Picture
  • Figure 14. Others Picture
  • Figure 15. Global Conjugate Vaccine Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 16. Global Conjugate Vaccine Sales Value Market Share by Type, 2024 & 2031
  • Figure 17. Global Conjugate Vaccine Sales Volume by Type (2020 VS 2024 VS 2031) & (Million Unit)
  • Figure 18. Global Conjugate Vaccine Sales Volume Market Share by Type, 2024 & 2031
  • Figure 19. Global Conjugate Vaccine Price by Type (2020-2031) & (USD/Unit)
  • Figure 20. Product Picture of Children
  • Figure 21. Product Picture of Adult
  • Figure 22. Global Conjugate Vaccine Sales Value by End Users (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 23. Global Conjugate Vaccine Sales Value Market Share by End Users, 2024 & 2031
  • Figure 24. Global Conjugate Vaccine Sales Volume by End Users (2020 VS 2024 VS 2031) & (Million Unit)
  • Figure 25. Global Conjugate Vaccine Sales Volume Market Share by End Users, 2024 & 2031
  • Figure 26. Global Conjugate Vaccine Price by End Users (2020-2031) & (USD/Unit)
  • Figure 27. North America Conjugate Vaccine Sales Value (2020-2031) & (US$ Million)
  • Figure 28. North America Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Europe Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. Europe Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • Figure 31. Asia Pacific Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Asia Pacific Conjugate Vaccine Sales Value by Region (%), 2024 VS 2031
  • Figure 33. South America Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. South America Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • Figure 35. Middle East & Africa Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. Middle East & Africa Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • Figure 37. Key Countries/Regions Conjugate Vaccine Sales Value (%), (2020-2031)
  • Figure 38. Key Countries/Regions Conjugate Vaccine Sales Volume (%), (2020-2031)
  • Figure 39. United States Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. United States Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 41. United States Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 42. Europe Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Europe Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Europe Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 45. China Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. China Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 47. China Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 48. Japan Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. Japan Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 50. Japan Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 51. South Korea Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. South Korea Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 53. South Korea Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 54. Southeast Asia Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 55. Southeast Asia Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 56. Southeast Asia Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 57. India Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 58. India Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 59. India Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 60. Conjugate Vaccine Industrial Chain
  • Figure 61. Conjugate Vaccine Manufacturing Cost Structure
  • Figure 62. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 63. Bottom-up and Top-down Approaches for This Report
  • Figure 64. Data Triangulation
  • Figure 65. Key Executives Interviewed